IDBiologics

Executive Summary

IDBiologics is a private biotechnology company founded in 2014, focused on discovering and developing human monoclonal antibodies (mAbs) for the prevention and treatment of infectious diseases. Leveraging a world-leading platform from Vanderbilt University Medical Center, the company rapidly identifies broad and potent neutralizing antibodies against viral targets. IDBiologics' mission is to solve infectious disease challenges through a diverse pipeline of therapeutic candidates. The company is headquartered in Memphis, Tennessee, and operates at the preclinical stage, with no disclosed clinical-stage assets. Given its proprietary platform and expertise in antibody discovery, IDBiologics is well-positioned to address unmet medical needs in infectious disease, though its valuation and funding details remain undisclosed. The company's success hinges on advancing lead candidates into clinical development and securing strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026Initiation of First-in-Human Phase 1 Trial for Lead mAb Candidate40% success
• Q2 2026Strategic Partnership or Licensing Deal with Major Pharma30% success
• Q3 2026Presentation of Preclinical Data at Major Infectious Disease Conference60% success